Promotion of platelet aggregation by sera from brucellosis patients with antiphosphatidylcholine antibodies
Results obtained in this study suggest that in human brucellosis there is an antibody response against platelet-activating factor (PAF) and phosphatidylcholine (PC). The specificity of the antiphospholipid response was determined by inhibition assays. The PAF molecule was able to inhibit the anti-PC...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2001 |
| País: | España |
| Institución: | Universidad de Navarra |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/23358 |
| Acceso en línea: | https://hdl.handle.net/10171/23358 |
| Access Level: | acceso abierto |
| Palabra clave: | Antibodies, Bacterial/blood/immunology Antibody Specificity Brucellosis/immunology/physiopathology |
| Sumario: | Results obtained in this study suggest that in human brucellosis there is an antibody response against platelet-activating factor (PAF) and phosphatidylcholine (PC). The specificity of the antiphospholipid response was determined by inhibition assays. The PAF molecule was able to inhibit the anti-PC activity of the brucellosis-control serum. This inhibition capacity of PAF was similar to that of the phosphorylcholine (PYC) group. These results suggest that the inhibition activity could be attributed to the PYC group present in both PAF and PC molecules. Consequently, these findings support an immunodominant role of PYC in the antiphospholipid response of brucellosis. Furthermore, sera from patients infected with Brucella organisms were able to cause platelet aggregation, as were brucella phospholipids, suggesting a possible role of the antiphospholipid antibodies and phospholipids in the inflammatory response in brucellosis. |
|---|